2013 - CTS 2013 Congress


Hot Topics in Cell Transplantation

3.1 - DNA Demethylation in Cell Transplantation

Presenter: Tiziana A.L., Brevini, Milan, Italy
Authors: Tiziana A.L. Brevini


“Epigenetic reprogramming of  human skin fibroblasts into insulin secreting cells”

Tiziana A.L. Brevini, Georgia Pennarossa, Sara Maffei, Marino Campagnol, Letizia Tarantini, Fulvio Gandolfi

Laboratory of Biomedical Embryology, Unistem, Centre for Stem Cell Research, Università degli Studi di Milano, Italy

The cells of an adult organism acquire their differentiated state through the epigenetic regulation of gene expression that leads to a progressive restriction in their options. Among the different mechanisms involved in lineage specification, DNA methylation plays a major role, therefore the use of a demethylating agent can be used to facilitate the transition of mature cells to a higher plasticity state and thus allow the direct conversion of an adult cell into another differentiated cell type. In our talk we will describe the use of the DNA methyltransferase inhibitor 5-azacytidine (5-aza-CR) to revert fibroblasts from their lineage commitment to a more pluripotent state. We will show that the short exposure to the epigenetic modifier is enough to trigger a transient higher plasticity window in fibroblasts that can then be re-addressed towards the endoderm lineage and pancreatic differentiation. At the end of the treatment, fibroblasts become pancreatic converted cells (PCC) that show an epithelial morphology, produce insulin, release the hormone in response to a physiological glucose challenge in vitro and are able to protect recipient mice against streptozotocin-induced diabetes, restoring normal processing of glucose. The conversion into pancreatic phenotype is obtained without any transgenic modification and avoids a stable pluripotent state which is unphysiological, inherently labile and makes cells prone to alterations. All these aspects, together with the easy accessibility of fibroblasts makes these cells excellent candidates for regenerative medicine and patient specific cell therapy (the authors performed the experiments with the support of Network Lombardo iPS (NetLiPS) Project ID 30190629 and are members of the COST Action FA1201 Epiconcept: Epigenetics and Periconception environment)

 


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi